George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 570.00
Bid: 560.00
Ask: 580.00
Change: 0.00 (0.00%)
Spread: 20.00 (3.571%)
Open: 570.00
High: 570.00
Low: 570.00
Prev. Close: 570.00
ELIX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission to AIM and First Day of Dealings

9 Jul 2020 08:00

RNS Number : 4531S
Elixirr International PLC
09 July 2020
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUE A VIOLATION OF THE SECURITIES LAWS OF THESE JURISDICTIONS.

For immediate release

9 July 2020

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or the "Group")

Admission to Trading on AIM

and

First Day of Dealings

 

Elixirr, an established, global award-winning challenger consultancy, is pleased to announce the admission of its entire issued and to be issued ordinary share capital to trading on the AIM Market of the London Stock Exchange. Admission will occur at 8.00 a.m. today, under the ticker "ELIX" and the ISIN GB00BLPHTX84.

The Company has successfully raised £20.0 million (before expenses) by way of an oversubscribed placing of 9,216,590 new Ordinary Shares with institutional and other investors at a price of 217 pence per Ordinary Share (the "Placing Price"). In addition, 2,304,148 existing Ordinary Shares have been placed on behalf of the Selling Shareholders at the Placing Price, raising gross proceeds of £5.0 million.

The Company's market capitalisation at the Placing Price on Admission is £98.1 million. finnCap is acting as Nominated Adviser and sole Broker to the Company.

The Company's AIM admission document is available to view on the Company's website: www.elixirr.com.

 

Stephen Newton, Chief Executive of Elixirr International plc commented:

"Listing on AIM today marks an incredible chapter in Elixirr's story. The vision I had for the firm in 2009 remains - to become a world-leading consultancy. Admission to the exchange will further support our reputation as the challenger consultancy and provide the capital to accelerate our integrated strategy, growing off the great platform we have created.

This huge achievement is a culmination of the exceptional work and partnership with our fantastic clients, our talented team and our trusted advisors.

Everyone within the business is looking forward to beginning our life as a public company which will see all Elixirr employees become shareholders to further align the business for continued success. "

 

For further Information please contact:

 

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

 

 

 

Public and Investor Relations contacts:

Caroline Pitt

Jazz Berry

 

finnCap Ltd (Nominated Adviser & Sole Broker)

Christopher Raggett, Simon Hicks, Kate Bannatyne (Corporate Finance)

Andrew Burdis, Sunila De Silva (ECM)

 

 

investor-relations@elixirr.com

 

 

+44 (0)20 7220 0500

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

 

Important notices

Capitalised terms used in the Company's AIM admission document dated 6 July 2020 have the same meanings in this announcement.

finnCap which is authorised and regulated in the United Kingdom by the Financial Conduct Authority is acting exclusively for the Company and no one else in connection with the Placing and Admission, and finnCap will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing and Admission or any other matters referred to in this announcement.

Neither finnCap, nor any of its subsidiary undertakings, affiliates or any of its directors, officers, employees, advisers, agents or any other person accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions contained in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith and any liability therefore is expressly disclaimed.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCRPMFTMTBMBBM
12
Date   Source Headline
24th Apr 20247:00 amRNSGrant of Share Options
22nd Apr 20247:00 amRNSFinal Results
8th Apr 20247:00 amRNSNotice of FY 23 Results and Investor Presentation
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing
13th Jun 20221:00 pmRNSResult of AGM
19th May 20227:00 amRNSPosting of Annual Report & Accounts
29th Apr 20224:07 pmRNSResult of Secondary Placing
28th Apr 20224:06 pmRNSProposed Secondary Placing
8th Apr 20224:15 pmRNSDirector/PDMR Shareholding
4th Apr 20227:00 amRNSFinal Results
18th Mar 20227:00 amRNSAcquisition of iOLAP and FY2022 Earnings
1st Feb 20227:00 amRNSTrading Update
30th Nov 20217:00 amRNSDirector/PDMR Shareholding
13th Oct 202111:41 amRNSResult of Secondary Placing
13th Oct 20217:00 amRNSProposed Secondary Placing
27th Sep 20217:00 amRNSInterim Results
17th Jun 20218:13 amRNSDirector/PDMR Shareholding
16th Jun 202112:21 pmRNSResult of AGM
16th Jun 20217:00 amRNSAGM Statement
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.